Karydas Daphne 4
4 · Syndax Pharmaceuticals Inc · Filed Feb 5, 2021
Insider Transaction Report
Form 4
Karydas Daphne
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-02-03+95,000→ 95,000 totalExercise: $21.36Exp: 2031-02-03→ Common Stock (95,000 underlying)
Footnotes (1)
- [F1]1/48th of the shares subject to the option shall vest monthly over a four-year period.